VPAC1 Receptors for Imaging Breast Cancer:A Feasibility Study

By February 28, 2013February 28th, 2021No Comments

This feasibility study demonstrated the compelling need for an innovative approach that would decrease the number of unnecessary benign biopsies while still detecting the malignancies. A high percentage of the breast biopsies that were performed in the United States have resulted in a benign diagnosis. These unnecessary biopsies create significant patient morbidity and potentially unnecessary health care costs. To detect BC, digital mammography, MRI, CT, sonography, 18F-FDG, and 99mTc-sestamibi have made significant advances.

However, these modalities have limited specificity, and all continue to produce many false-positive and false-negative results (3–12). At an average cost of $5,000–$6,000 for each biopsy, unnecessary benign biopsies represent a serious health care burden.

Read more…